At a glance
ClinicalIndex Comparison RecordN/ACompleted· 129 enrolled
Drug / intervention
Superion™ IDSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postmarket Outcomes Study for Evaluation of the Superion™ Spacer
In Brief
An observational study evaluating Superion™ IDS for Lumbar Spinal Stenosis. Completed, enrolled 129 participants across 23 sites.
Detailed Summary
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLumbar Spinal Stenosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionMar 2023
TodayJul 2026
First PostedSep 24, 2020
Enrollment StartOct 8, 2020
Primary CompletionMar 20, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.8 years ago
Interventions
Superion™ IDSdevice
All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.